For individuals, research teams or institutions for work conducted on relevant toxicity pathways. Outstanding research producing an effective non-animal safety test based on an approach other than toxicity pathways, where none existed before, may also be considered.
There is a £50,000 prize fund shared between all the winners of the Science Prize.
21st Century Toxicology is a new approach to safety testing which is exciting regulators, toxicologists, campaigners and companies around the world. It has become possible because of advances in biology, genetics, computer science and robotics.
It offers better relevance to humans (rather than using mice, rats and rabbits), and will explain the underlying causes of toxicity. Unlike animal methods, the new tests will help predict human variability and differential effects on embryos, children and adults. And as the superior scientific basis of the new approach is recognised, outdated animal tests will be replaced.
Background Papers and Materials
Entries for 2018 will open on Wednesday 4th April.
You can enter yourself or your own organisation – please note that we do not accept nominations on behalf of other people or organisations.
Prof Marcel Leist, University of Konstanz / CAAT-Europe, Germany (£40,000)
This group focuses on the development of toxicological tests that are based on the use of human cells. Their vision is that eventually, when all these tests are established, the hazard can be predicted, based on an in vitro test battery.
Dr. Daniele Zink and Dr. Lit-Hsin Loo, (A*STAR), Singapore (£10,000)
A research team led by Dr Daniele Zink from the Institute of Bioengineering and Nanotechnology and Dr Lit-Hsin Loo from the Bioinformatics Institute of the Agency for Science, Technology and Research in Singapore have developed animal-free methods that can accurately predict the toxic effects of chemicals on the human kidney.
Oncotheis, Switzerland (£25,000)
Oncotheis have engineered an innovative human lung cancer tissue culture model to test in vitro both the effectiveness and the toxicity of investigational therapeutics while sparing the lives of animals.
Prof Michael L. Shuler & Team, USA (£25,000)
Professor Michael L. Shuler, Cornell University & Hesperos
Asst. Professor Mandy B. Esch, Syracuse University
Asst. Professor Gretchen J. Mahler, SUNY Binghampton University
Professor Tracy Stokol, Cornell University
Dr James Hickman, University of Central Florida & Hesperos
Since 1989 they have developed in vitro systems to predict human response to drugs by using physiologically-based pharmacokinetic (PBPK) models to guide the development of experimental systems that mimic human response to drugs. These systems have been called “Body-on-a-Chip” systems.
Professor Roland Grafström and Dr. Pekka Kohonen, Karolinska Institutet, Sweden (£50,000)
The Grafström laboratory has developed a cancer biology work and Tox21 Century Toxicology-inspired approach for replacing toxicity testing in animals with informatics-driven data analysis of human cell cultures exposed to toxic agents.
QSAR and Molecular Modelling Group, Liverpool John Moores University, UK (£25,000)
For their work developing computational alternatives to animal testing to predict the effects of chemicals.
The Lung & Particles Research Group, Cardiff University, UK (£25,000)
For their work developing non-animal replacement models of the human respiratory system for inhalation toxicology applications.
The Institute for Health and Consumer Protection, European Commission Joint Research Centre, Italy (£50,000)
For its work on toxicity pathways in heptatoxicology and developmental toxicology.